• OPEN AN ACCOUNT
Indian Indices
Nifty
24,619.35 131.95
(0.54%)
Sensex
80,597.66 57.75
( 0.07%)
Bank Nifty
55,181.45 137.75
( 0.25%)
Nifty IT
34,692.95 18.65
( 0.05%)
Global Indices
Nasdaq
44,917.96 438.34
(0.99%)
Dow Jones
6,479.45 12.69
(0.20%)
Hang Seng
42,649.26 -625.41
(-1.45%)
Nikkei 225
9,165.23 17.42
(0.19%)
Forex
USD-INR
87.63 0.02
(0.02%)
EUR-INR
102.01 0.08
(0.08%)
GBP-INR
118.04 0.28
(0.24%)
JPY-INR
0.59 0.00
(-0.19%)

EQUITY - MARKET SCREENER

Docmode Health Technologies Ltd
Industry :  Miscellaneous
BSE Code
ISIN Demat
Book Value()
79225
INE0OGG01015
26.5775741
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
DHTL
0
16.22
EPS(TTM)
Face Value()
Div & Yield %
0
10
0
 

Cipla's Bengaluru facility receives VAI classification from USFDA
Aug 05,2025
The classification was communicated to the company via email on 4 August 2025. The inspection was conducted under the USFDA’s current Good Manufacturing Practices (cGMP) framework from 26 May to 30 May 2025. In an earlier exchange filing dated May 30, Cipla had disclosed that the inspection concluded with one observation issued in Form 483.

The company reiterated its commitment to compliance and stated that it will work closely with the USFDA to address the observation comprehensively within the stipulated timeframe.

Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolios in our home markets of India, South Africa, North America, and key regulated and emerging markets.

Cipla reported 10.18% increase in consolidated net profit to Rs 1,297.62 crore on a 3.93% rise in total revenue from operations to Rs 6,957.47 crore in Q1 FY26 over Q1 FY25.

The counter shed 1.42% to Rs 1,494 on the BSE